Meshack Nhano
Tanzania’s decision to embrace a new US$3.1 billion health partnership with the United States has placed the country at the centre of a wider African debate over sovereignty, foreign aid and the changing nature of international health cooperation.
The agreement comes after months of controversy surrounding the United States’ new bilateral health strategy, which replaced aspects of traditional development assistance with government-to-government agreements negotiated under Washington’s “America First Global Health Strategy.”
Across Africa, the proposed agreements generated significant resistance. Zimbabwe reportedly walked away from negotiations over concerns relating to access to health data and biological samples, while Zambia challenged provisions linked to minerals. In Kenya, concerns over data privacy and other conditions triggered legal and civil society scrutiny. More than 60 civil society organisations across Africa also raised concerns about the broader framework of the agreements.
Against that background, Tanzania took a different path.
Rather than rejecting the negotiations outright, Tanzanian authorities argued that the country entered discussions with clear national interests and established limits on issues considered sensitive to national sovereignty.
Health Minister Mohamed Mchengerwa said during negotiations that Tanzania had deliberately adopted a firm position on contentious matters that had created controversy in other African countries. He argued that Tanzania’s proposed arrangement could become a model for the continent because national interests had been prioritised.
The final five-year agreement, signed in July 2026, involves approximately US$3.1 billion in combined commitments. Tanzania is expected to contribute around US$1.8 billion while the United States intends to provide more than US$1.3 billion towards strengthening health systems, disease surveillance, infrastructure and national health security.
However, Tanzania’s decision has not ended the controversy. Questions have continued over the protection of health data, the role of American companies and technologies, and the long-term implications of the agreement for Tanzania’s pharmaceutical and biomedical industries.
The government has sought to address some of those concerns by confirming that Tanzania did not accept provisions requiring the sharing of biological specimens with the United States. Officials maintain that the country negotiated a more favourable agreement than some other African governments.
The debate now presents a larger question for Africa. Should African countries reject controversial international agreements outright when sensitive conditions emerge, or should they remain at the negotiating table and attempt to reshape the terms in favour of their national interests?
Tanzania’s experience suggests a third option between unconditional acceptance and outright rejection: negotiation with clearly defined national red lines.
This is the argument Tanzanian authorities are effectively presenting to other African countries. The success of that approach, however, will ultimately depend on implementation. The real test will be whether Tanzania emerges from the five-year agreement with stronger institutions, greater domestic health financing, improved pharmaceutical capacity and full control over its strategic health resources.
If those objectives are achieved, Tanzania could indeed provide an important model for African countries negotiating increasingly complex partnerships with global powers. But if the agreement creates new dependencies or compromises domestic capacity, the controversy surrounding America’s new health diplomacy will remain unresolved.
For now, Tanzania has positioned itself as a country attempting to demonstrate that African governments do not necessarily have to choose between rejecting foreign partnerships and accepting unfavourable conditions.
